New York State Common Retirement Fund Has $2.23 Million Stock Position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

New York State Common Retirement Fund raised its position in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) by 155.3% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 92,001 shares of the biopharmaceutical company's stock after purchasing an additional 55,968 shares during the period. New York State Common Retirement Fund owned 0.08% of Catalyst Pharmaceuticals worth $2,231,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the company. Cambridge Investment Research Advisors Inc. bought a new position in shares of Catalyst Pharmaceuticals in the 1st quarter valued at approximately $484,000. Principal Financial Group Inc. raised its stake in shares of Catalyst Pharmaceuticals by 2.8% in the 1st quarter. Principal Financial Group Inc. now owns 617,506 shares of the biopharmaceutical company's stock valued at $14,975,000 after acquiring an additional 17,018 shares in the last quarter. Spire Wealth Management raised its stake in shares of Catalyst Pharmaceuticals by 27.7% in the 1st quarter. Spire Wealth Management now owns 18,429 shares of the biopharmaceutical company's stock valued at $447,000 after acquiring an additional 4,000 shares in the last quarter. Teacher Retirement System of Texas raised its stake in shares of Catalyst Pharmaceuticals by 18.7% in the 4th quarter. Teacher Retirement System of Texas now owns 31,655 shares of the biopharmaceutical company's stock valued at $661,000 after acquiring an additional 4,996 shares in the last quarter. Finally, Natixis Advisors LLC raised its stake in shares of Catalyst Pharmaceuticals by 29.8% in the 4th quarter. Natixis Advisors LLC now owns 59,253 shares of the biopharmaceutical company's stock valued at $1,237,000 after acquiring an additional 13,616 shares in the last quarter. 79.22% of the stock is owned by hedge funds and other institutional investors.

Catalyst Pharmaceuticals Stock Performance

Shares of NASDAQ:CPRX traded down $0.05 during trading on Friday, hitting $20.97. 908,559 shares of the stock were exchanged, compared to its average volume of 1,297,321. Catalyst Pharmaceuticals, Inc. has a 1-year low of $15.34 and a 1-year high of $26.58. The company has a market capitalization of $2.56 billion, a price-to-earnings ratio of 13.36, a price-to-earnings-growth ratio of 0.85 and a beta of 0.66. The company's fifty day simple moving average is $22.96 and its 200-day simple moving average is $22.89.

Wall Street Analysts Forecast Growth

Separately, Cantor Fitzgerald raised Catalyst Pharmaceuticals to a "strong-buy" rating in a research note on Thursday, June 5th. Six analysts have rated the stock with a buy rating and three have given a strong buy rating to the stock. Based on data from MarketBeat, Catalyst Pharmaceuticals has an average rating of "Buy" and an average price target of $32.83.

Insider Buying and Selling at Catalyst Pharmaceuticals

In related news, insider Gary Ingenito sold 44,000 shares of the business's stock in a transaction on Wednesday, May 14th. The stock was sold at an average price of $23.63, for a total value of $1,039,720.00. Following the sale, the insider owned 68,873 shares of the company's stock, valued at $1,627,468.99. The trade was a 38.98% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Preethi Sundaram sold 1,600 shares of the business's stock in a transaction on Wednesday, June 11th. The shares were sold at an average price of $26.42, for a total value of $42,272.00. Following the completion of the sale, the insider directly owned 41,081 shares in the company, valued at approximately $1,085,360.02. This represents a 3.75% decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 247,924 shares of company stock worth $5,879,369. 10.40% of the stock is owned by insiders.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.